Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Oral toxicity management in head and neck cancer patients treated with chemotherapy and radiation: Xerostomia and trismus (Part 2). Literature review and consensus statement.
Buglione M, Cavagnini R, Di Rosario F, Maddalo M, Vassalli L, Grisanti S, Salgarello S, Orlandi E, Bossi P, Majorana A, Gastaldi G, Berruti A, Trippa F, Nicolai P, Barasch A, Russi EG, Raber-Durlacher J, Murphy B, Magrini SM. Buglione M, et al. Among authors: trippa f. Crit Rev Oncol Hematol. 2016 Jun;102:47-54. doi: 10.1016/j.critrevonc.2016.03.012. Epub 2016 Mar 11. Crit Rev Oncol Hematol. 2016. PMID: 27061883 Review.
Mucositis in head and neck cancer patients treated with radiotherapy and systemic therapies: Literature review and consensus statements.
De Sanctis V, Bossi P, Sanguineti G, Trippa F, Ferrari D, Bacigalupo A, Ripamonti CI, Buglione M, Pergolizzi S, Langendjik JA, Murphy B, Raber-Durlacher J, Russi EG, Lalla RV. De Sanctis V, et al. Among authors: trippa f. Crit Rev Oncol Hematol. 2016 Apr;100:147-66. doi: 10.1016/j.critrevonc.2016.01.010. Epub 2016 Feb 1. Crit Rev Oncol Hematol. 2016. PMID: 26947812 Review.
Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study.
Triggiani L, Alongi F, Buglione M, Detti B, Santoni R, Bruni A, Maranzano E, Lohr F, D'Angelillo R, Magli A, Bonetta A, Mazzola R, Pasinetti N, Francolini G, Ingrosso G, Trippa F, Fersino S, Borghetti P, Ghirardelli P, Magrini SM. Triggiani L, et al. Among authors: trippa f. Br J Cancer. 2017 Jun 6;116(12):1520-1525. doi: 10.1038/bjc.2017.103. Epub 2017 Apr 27. Br J Cancer. 2017. PMID: 28449007 Free PMC article.
Corrigendum to "The vicious circle of treatment-induced toxicities in locally advanced head and neck cancer and the impact on treatment intensity" [Crit. Rev. Oncol./Hematol. 116 (2017) 82-88].
Bossi P, Cossu Rocca M, Corvò R, Depenni R, Guardamagna V, Marinangeli F, Miccichè F, Trippa F. Bossi P, et al. Among authors: trippa f. Crit Rev Oncol Hematol. 2017 Nov;119:29. doi: 10.1016/j.critrevonc.2017.09.012. Epub 2017 Sep 28. Crit Rev Oncol Hematol. 2017. PMID: 29065982 No abstract available.
Diarrhoea in adult cancer patients: ESMO Clinical Practice Guidelines.
Bossi P, Antonuzzo A, Cherny NI, Rosengarten O, Pernot S, Trippa F, Schuler U, Snegovoy A, Jordan K, Ripamonti CI; ESMO Guidelines Committee. Bossi P, et al. Among authors: trippa f. Ann Oncol. 2018 Oct 1;29(Suppl 4):iv126-iv142. doi: 10.1093/annonc/mdy145. Ann Oncol. 2018. PMID: 29931177 Free article. No abstract available.
Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter study.
Triggiani L, Mazzola R, Magrini SM, Ingrosso G, Borghetti P, Trippa F, Lancia A, Detti B, Francolini G, Matrone F, Bortolus R, Fanetti G, Maranzano E, Pasqualetti F, Paiar F, Bonù ML, Magli A, Bruni A, Mazzeo E, Franzese C, Scorsetti M, Alongi F, Jereczek-Fossa BA, Ost P, Buglione M. Triggiani L, et al. Among authors: trippa f. World J Urol. 2019 Dec;37(12):2631-2637. doi: 10.1007/s00345-019-02717-7. Epub 2019 Mar 11. World J Urol. 2019. PMID: 30859273
[No title available]
[No authors listed] [No authors listed] PMID: 32169222
Stereotactic ablative radiotherapy in castration-resistant prostate cancer patients with oligoprogression during androgen receptor-targeted therapy.
Ingrosso G, Detti B, Fodor A, Caini S, Borghesi S, Triggiani L, Trippa F, Russo D, Bruni A, Francolini G, Lancia A, Marinelli L, Di Muzio N, Livi L, Magrini SM, Maranzano E, Musio D, Aristei C, Valeriani M. Ingrosso G, et al. Among authors: trippa f. Clin Transl Oncol. 2021 Aug;23(8):1577-1584. doi: 10.1007/s12094-021-02553-5. Epub 2021 Jan 25. Clin Transl Oncol. 2021. PMID: 33495981
Upfront metastasis-directed therapy in oligorecurrent prostate cancer does not decrease the time from initiation of androgen deprivation therapy to castration resistance.
Triggiani L, Mazzola R, Tomasini D, Bruni A, Alicino G, Matrone F, Bortolus R, Francolini G, Detti B, Magli A, Bonù ML, Ingrosso G, Lancia A, Trippa F, Maranzano E, Franzese C, Ghirardelli P, Vavassori V, Scorsetti M, Alongi F, Magrini SM. Triggiani L, et al. Among authors: trippa f. Med Oncol. 2021 May 18;38(6):72. doi: 10.1007/s12032-021-01518-6. Med Oncol. 2021. PMID: 34008151 Free PMC article.
69 results